Use Of Bgp15 To Stimulate Mitochondrial Fusion

  • Published: Jan 4, 2018
  • Earliest Priority: Jul 01 2016
  • Family: 2
  • Cited Works: 61
  • Cited by: 0
  • Cites: 3
  • Additional Info: Cited Works Full text
Abstract

The present invention relates to the use of 0-(3-piperidino-2-hydroxy-l-propyl)- nicotinic amidoxime (BGP15), its tautomers, enantiomers and pharmaceutically acceptable salts thereof the treatment of diseases characterised at least in part by an excessive mitochondrial fragmentation activity or by a reduced mitochondrial fusion activity such as pulmonary fibrosis, age related macular degeneration, retinitis pigmentosa, heart failure with preserved ejection fraction, an inherited mtDNA depletion disorder (such as Alper's disease) or an inherited mtDNA deletion/mutation disorder (such as progressive external ophthalmoplegia, an ataxia-neuropathy spectrum disorder or mitochondrial neurogastrointestinal encephalomyopathy).


Claims
Download PDF
Document Preview
Document History
  • Publication: Jan 4, 2018
  • Application: Jun 29, 2017
    WO IB 2017053920 W
  • Priority: Jul 1, 2016
    EP EP 16177514 A

Download Citation


Sign in to the Lens

Feedback